Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited covers the month of December 2021, with the report signed on January 3, 2022. The filing discloses corporate governance changes rather than financial performance results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to the disclosure of a director's resignation and associated interest notices.
Material Changes
The primary material change disclosed is the resignation of Mitchell Kaye as a non-executive director of the Company, effective December 31, 2021. A Final Director's Interest Notice was lodged with the Australian Securities Exchange (ASX) to disclose Mr. Kaye's interest in the Company's securities and contracts.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific business risks. The document serves solely to comply with reporting requirements for the director's departure.
Investor Verification Checklist
- Verify the effective date of Mitchell Kaye's resignation (December 31, 2021).
- Review the attached Final Director's Interest Notice (Exhibit 99.2) for details on Mr. Kaye's remaining holdings.
- Confirm the composition of the Board of Directors following this resignation.